SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy
Title:
SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy
Author:
Van Der Heijden, M.S. Cutie, C. Hampras, S. Indoria, C. Stewart, R. Acharya, M. Stromberg, K. Li, X. Beeharry, N. Maffeo, J. Jacob, J.M. Tsiatas, M.
Appeared in:
European urology open science
Paging:
Volume 33 () nr. S3 pages S389-S390
Year:
2021
Contents:
Publisher:
European Association of Urology. Published by Elsevier B.V.